Links:
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. An pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study.
An open-label, multicenter, randomized trial enrolled
Read Article
Have you ever seen multicentric reticulohistiocytosis? Don't worry, it's a rare non-Langerhans cell histiocytosis condition, characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and has only been described in fewer than 500 cases reported worldwide.
Read Article
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Read Article
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Read Article
New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant and often underrecognized public health burden.
Read Article
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or mindfulness) may not be effective.
Read Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Read Article
While hydroxychloroquine (HCQ) is thought to be a very safe drug, its ocular risk profile is probably more serious than appreciated. A comprehensive review published in the Journal of Rheumatology discusses HCQ pharmacokinetics, mechanisms of retinal toxicity, risk stratification, and evidence-
Read Article
A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.
Cohorts were derived from the Clinical Practice Research
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
